DSpace@İnönü

Yazar "Tabak, F" için Araştırma Çıktıları | Pubmed İndeksli Yayınlar Koleksiyonu listeleme

Yazar "Tabak, F" için Araştırma Çıktıları | Pubmed İndeksli Yayınlar Koleksiyonu listeleme

Sırala: Sıra: Sonuçlar:

  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...
  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...
  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...
  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and 
    Idilman, R; Demir, M; Aladag, M; Erol, C; Cavus, B; Iliaz, R; Koklu, H; Cakaloglu, Y; Sahin, M; Ersoz, G; Koksal, I; Karasu, Z; Ozgenel, M; Turan, I; Gunduz, F; Ataseven, H; Akdogan, M; Kiyici, M; Koksal, AS; Akhan, S; Gunsar, F; Tabak, F; Kaymakoglu, S; Akarca, US; Akarsu, M; Alkim, H; Araz, F; Ates, F; Aygen, B; Balik, I; Barut, HS; Baysal, B; Bolat, A; Celik, I; Cosgun, S; Ensaroglu, F; Gokcan, H; Gurel, S; Gursoy, S; Inkaya, AC; Kamilli, C; Kav, T; Kuruuzum, Z; Onder, FO; Ormeci, N; Ozbakir, O; Ozenirler, S; Ozer, B; Ozkan, H; Poturoglu, S; Senates, E; Simsek, H; Toka, B; Unal, H; Yaras, S; Yildirim, AE; Yildirim, B; Yilmaz, B; Yilmaz, H; Yozgat, A; Yurdaydin, C (2019)
    The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease ...